Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Gains from Investment Securities: 2020-2024

Historic Gains from Investment Securities for Therapeutics (RAPT) over the last 2 years, with Sep 2024 value amounting to $5.2 million.

  • Therapeutics' Gains from Investment Securities was N/A to $5.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $5.2 million, marking a year-over-year change of. This contributed to the annual value of $100,000 for FY2024, which is 85.71% down from last year.
  • Per Therapeutics' latest filing, its Gains from Investment Securities stood at $5.2 million for Q3 2024, which was down 6.66% from $5.6 million recorded in Q2 2024.
  • In the past 5 years, Therapeutics' Gains from Investment Securities registered a high of $6.6 million during Q1 2022, and its lowest value of $700,000 during Q4 2023.
  • For the 3-year period, Therapeutics' Gains from Investment Securities averaged around $4.2 million, with its median value being $5.4 million (2024).
  • In the last 5 years, Therapeutics' Gains from Investment Securities skyrocketed by 126.85% in 2022 and then tumbled by 52.64% in 2023.
  • Quarterly analysis of 5 years shows Therapeutics' Gains from Investment Securities stood at $2.4 million in 2020, then remained steady at $2.4 million in 2021, then tumbled by 38.42% to $1.5 million in 2022, then plummeted by 52.64% to $700,000 in 2023, then reached $5.2 million in 2024.
  • Its Gains from Investment Securities stands at $5.2 million for Q3 2024, versus $5.6 million for Q2 2024 and $5.5 million for Q1 2024.